Jazz Pharmaceuticals JAZZ Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $293.1M— | —— | $251.41M+135% | -$718.47M-677% | -$92.5M-148% | ||
| $9.1M-3.5% | $9.43M-4.6% | $9.88M-17.2% | $11.93M+14.7% | $10.4M+9.3% | ||
| $74.5M+5.1% | $70.85M-19.6% | $88.13M+36.7% | $64.45M-4.8% | $67.7M-3.5% | ||
| -$66.2M-4.6% | -$63.31M+76.7% | -$271.41M-308% | -$66.45M-51.7% | -$43.8M-1,760% | ||
| $122.8M— | —— | —— | —— | $0— | ||
| $6.5M-90.1% | $65.81M+29.1% | $51M-8.1% | $55.47M+184% | -$66M— | ||
| $77.8M— | $0-100% | $31.91M+21.5% | $26.25M-26.3% | $35.6M+90.7% | ||
| -$21.4M— | —— | $62.36M— | —— | $19.1M+709% | ||
| -$7.9M-130% | $26.17M-79.3% | $126.28M+149% | -$256.35M-242% | $181M+509% | ||
| -$51.9M-371% | -$11.01M+41.5% | -$18.82M-37,748% | $50K-93.4% | $752K-98.1% | ||
| $12.2M-46.3% | $22.73M+4,196% | $529K-71.6% | $1.86M-35.8% | $2.9M+107% | ||
| -$3.9M— | —— | -$1.02M+92.5% | -$13.54M-308% | $6.5M— | ||
| $37.4M— | —— | $12.74M-72.5% | $46.27M+256% | $13M+137% | ||
| $172.3M+1.5% | $169.74M+0.8% | $168.37M+3.9% | $162.1M+5.0% | $154.4M-2.8% | ||
| $408.2M+12.6% | $362.52M-23.6% | $474.62M+434% | $88.84M-79.3% | $429.8M+7.8% | ||
| $19.7M+17.8% | $16.73M+10.2% | $15.18M+17.2% | $12.95M-6.8% | $13.9M+4.6% | ||
| $500M-2.0% | $510.1M-20.3% | $640.13M+167% | $239.95M-45.5% | $440.1M-6.4% | ||
| $520M+189% | $180M-55.0% | $400M-14.9% | $470M+51.6% | $310M+6.9% | ||
| $200M— | —— | —— | —— | $0— | ||
| $0-100% | $53.5M+78.3% | $30M— | $0-100% | $25M— | ||
| $123.1M+133% | -$372.16M-13.5% | -$327.8M+48.9% | -$640.95M-279% | -$169M+12.6% | ||
| $32.9M-61.4% | $85.19M+11,522% | $733K-93.0% | $10.44M-9.2% | $11.5M+25.1% | ||
| $103.6M+5,090% | $2M-47.6% | $3.81M+72.3% | $2.21M-96.7% | $67.2M+1,578% | ||
| -$78.5M— | $0+100% | -$10.83M+91.3% | -$124.49M+84.7% | -$813.5M— | ||
| -$400K-1,312% | $33K-83.7% | $203K-95.6% | $4.62M+172% | $1.7M+174% | ||
| $452.4M— | —— | —— | -$671.98M-22.0% | -$551M-383% | ||
| —— | $62.14M0.0% | $62.14M0.0% | $62.14M0.0% | $62.14M-21.0% | ||
| —— | $30.45M0.0% | $30.45M0.0% | $30.45M0.0% | $30.45M+6.0% | ||
| $172.3M+1.5% | $169.74M+0.8% | $168.37M+3.9% | $162.1M+5.0% | $154.4M-2.8% | ||
| $9.1M-3.5% | $9.43M-4.6% | $9.88M-17.2% | $11.93M+14.7% | $10.4M+9.3% | ||
| $122.8M— | —— | —— | —— | $0— | ||
| -$51.9M-88.8% | -$27.49M— | —— | —— | -$41.4M-281% | ||
| $37.5M-7.6% | $40.6M+0.6% | $40.36M+8.8% | $37.09M+24.0% | $29.9M-20.9% | ||
| $4.7M-11.8% | $5.33M+0.6% | $5.3M+10.1% | $4.81M-71.8% | $17.1M+452% | ||
| -$3.9M— | —— | -$1.02M+92.5% | -$13.54M-308% | $6.5M— | ||
| $14.2M+245% | $4.11M-50.0% | $8.22M+459% | $1.47M-72.2% | $5.3M-55.4% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $0-100% | $53.5M+78.3% | $30M— | $0-100% | $25M— | ||
| $77.2M— | —— | —— | —— | $0— | ||
| $520M+189% | $180M-55.0% | $400M-14.9% | $470M+51.6% | $310M+6.9% | ||
| $200M— | —— | —— | —— | $0— | ||
| $32.9M-61.4% | $85.19M+11,522% | $733K-93.0% | $10.44M-9.2% | $11.5M+25.1% | ||
| $7.8M+0.6% | $7.75M0.0% | $7.75M+0.6% | $7.7M-99.0% | $757.8M+9,678% | ||
| —— | $30.45M0.0% | $30.45M0.0% | $30.45M0.0% | $30.45M+6.0% | ||
| $388.5M+12.4% | $345.79M-24.7% | $459.44M+505% | $75.89M-81.8% | $415.9M+7.9% | ||
| $388.5M+12.4% | $345.79M-24.7% | $459.44M+505% | $75.89M-81.8% | $415.9M+7.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Jazz Pharmaceuticals generate?
- Jazz Pharmaceuticals (JAZZ) generated $1.3B in operating cash flow over the trailing twelve months.
- What is Jazz Pharmaceuticals's free cash flow?
- After $64.6M of capital expenditures, Jazz Pharmaceuticals's free cash flow was $1.3B over the trailing twelve months, down 16.1% year over year.
- Where does Jazz Pharmaceuticals's cash flow data come from?
- Every line is extracted from Jazz Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
